An experimental stem cell therapy has shown encouraging signs of improving disease activity in people with difficult-to-treat lupus, raising hopes for a potential new treatment option for patients who do not respond adequately to conventional therapies.
However, the Phase II clinical trial, supported by the Lupus Foundation of America (LFA), failed to meet its primary efficacy target, underscoring the need for further research before the treatment can be considered a proven therapeutic option.
The study, known as the Mesenchymal Stromal Cells in Systemic Lupus Erythematosus (MiSLE) trial, evaluated a single infusion of umbilical cord-derived mesenchymal stromal cells (MSCs) in adults with active systemic lupus erythematosus (SLE).
While the combined low- and high-dose treatment groups did not demonstrate a statistically significant improvement over placebo at 24 weeks, patients receiving the higher dose showed stronger treatment responses and encouraging signs of reduced disease activity.
The findings have prompted researchers to plan a confirmatory trial focusing on the higher dose.
“The improvements in lupus activity we observed, especially among patients who received the higher dose, are promising and give us a clearer direction for future research,” said D Kamen of Medical University of South Carolina.
“We now intend to test these findings in a confirmatory trial of the higher 5 × 10⁶ cells/kg dose, including evaluation of repeat dosing to determine whether the early responses can be sustained over time.”
The trial enrolled 81 patients across nine clinical centres in the United States. Participants received either a low dose of MSCs (one million cells per kilogram), a higher dose (five million cells per kilogram), or a placebo.
At Week 24, 38.9% of participants receiving MSC treatment met the modified SLE Responder Index-4 (SRI-4) criteria, compared with 23.1% in the placebo group. Although the 15.8-percentage-point difference favoured treatment, it did not achieve statistical significance.
The higher-dose group, however, recorded a stronger response.
Nearly half (48.1%) of patients receiving five million cells per kilogram met the response criteria, compared with 29.6% in the lower-dose group and 23.1% in the pooled placebo group.
The difference between the higher-dose and placebo groups approached statistical significance, offering researchers a potential direction for further investigation.
Other secondary analyses also identified encouraging signals. Using the unmodified SRI-4 criteria, researchers found significant benefits for the higher-dose group compared with its within-cohort placebo group at Weeks 12, 16 and 20.
A per-protocol analysis, which excluded participants with major deviations from the study protocol before Week 24, showed an even stronger response. In this analysis, 68.4% of patients receiving the higher dose responded, compared with 30% in the pooled placebo group.
Researchers also tracked changes in disease activity using the SLE Disease Activity Index (SLEDAI). At Week 12, median scores fell by four points in both MSC treatment groups, compared with a two-point reduction among placebo recipients.
By Week 24, the higher-dose group recorded a greater median reduction than the other two groups. However, differences in baseline disease activity limit direct comparisons between the groups.
The study also examined the safety of the treatment through Week 52.
Serious adverse events were reported in 27.8% of participants who received MSC therapy, compared with 14.8% of those given placebo. The incidence varied considerably between the treatment groups, at 44.4% in the low-dose cohort and 11.1% in the higher-dose cohort.
None of the serious adverse events was attributed to the study drug.
Serious infections occurred in 7.4% of MSC-treated participants and 3.7% of placebo recipients, with fewer infections reported in the higher-dose MSC group.
One death by suicide occurred in the placebo group early in the study. No deaths were reported among the 54 participants who received MSC treatment.
The safety findings are encouraging, particularly in the higher-dose group, although the differences in adverse events highlight the importance of continued evaluation in larger studies.
Mesenchymal stromal cells are derived in this trial from donated umbilical cord tissue and are being investigated for their ability to regulate immune activity.
Their potential is particularly relevant to lupus, a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs, often affecting multiple organ systems.
The MiSLE trial is the first multicentre, randomised, double-blind, placebo-controlled study to evaluate allogeneic umbilical cord-derived MSCs in adults with active systemic lupus erythematosus.
Of the 87 participants randomised into the study, 81 received an infusion: 54 received MSCs and 27 received placebo. The primary efficacy analysis included 80 participants after one placebo recipient withdrew consent.
Participants had been living with lupus for a median of 12.9 years at enrolment. Approximately 89% of those who received an infusion were women, while 36% were Black.
The treatment was administered intravenously alongside standard lupus care. Participants were assigned to one of two sequential dose cohorts and received either one million or five million cells per kilogram of body weight.
After Week 24, participants in all groups could receive immunosuppressants, biologic therapies or prednisone at any dose, which is an important consideration when interpreting longer-term disease activity results.
The Lupus Foundation of America has supported research into mesenchymal stromal cells since 2012. In 2018, it announced a $3.8 million commitment towards the Phase II trial.
The MiSLE study was funded by the Lupus Foundation of America and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The foundation also supported public awareness efforts and participant recruitment.
The study was authored by Gary S. Gilkeson, Distinguished University Professor of Medicine, Microbiology and Immunology at the Medical University of South Carolina (MUSC). D Kamen co-authored and presented the findings.
Louise Vetter, President and CEO of the Lupus Foundation of America, said the findings represented an important step towards addressing the unmet needs of people living with the disease.
“People living with lupus deserve more than treatments that simply manage their symptoms. They deserve new options that offer hope for better disease control, improved quality of life and a future where lupus no longer dictates how they live,” said Louise Vetter, President and CEO of the Lupus Foundation of America.
“MiSLE reflects years of support in an approach with the potential to address this unmet need. We are extremely encouraged by these findings and deeply grateful to the participants, families and research teams who are helping drive the needle forward towards a cure.”